To further explain the enhanced antitumour ability of AXL-CAR T cells in vivo, we sacrificed 5 mice in the combination and AXL-CAR T groups on day 33 and 42 and sorted tumour-infiltrating CAR T cells to perform a series of tests. The gene discussed is AXL; the disease is neoplasm.